Welcome to our dedicated page for EVOMMUNE news (Ticker: EVMN), a resource for investors and traders seeking the latest updates and insights on EVOMMUNE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EVOMMUNE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EVOMMUNE's position in the market.
Evommune (NYSE: EVMN) reported Q3 2025 results and a business update highlighting upcoming clinical milestones and its recent IPO. The company expects three Phase 2 readouts in 2026 across lead programs EVO756 (MRGPRX2 antagonist) and EVO301 (IL-18 inhibitor), including Phase 2b top-line data in CSU in 1H26 and Phase 2a/2b AD readouts in 1H–2H26. The company completed an IPO in November 2025, raising $172.5 million gross proceeds. Q3 financials: $10.0M revenue (collaboration with Maruho), $76.0M cash and investments as of Sept 30, 2025, R&D expense of $19.6M, and net loss of $12.5M.
Evommune (NYSE:EVMN) priced its initial public offering of 9,375,000 common shares at $16.00 per share, with gross proceeds expected to be $150 million before underwriting discounts, commissions, and expenses. Underwriters have a 30-day option to purchase up to an additional 1,406,250 shares.
The shares are expected to begin trading on the New York Stock Exchange on November 6, 2025 under ticker EVMN, and the offering is expected to close on November 7, 2025, subject to customary closing conditions.
Evommune (NYSE:EVMN) announced the commencement of a proposed initial public offering on October 17, 2025 with a registration statement filed on Form S-1.
The company is offering 9,375,000 shares of common stock with an expected price range of $15.00 to $17.00 per share, and intends to grant underwriters a 30-day option for up to 1,406,250 additional shares. Evommune has applied to list its shares on the New York Stock Exchange under the symbol EVMN, and expects the registration statement to become automatically effective on November 5, 2025 pursuant to Section 8(a) of the Securities Act, subject to SEC and federal government operations.
FAQ
What is the current stock price of EVOMMUNE (EVMN)?
What is the market cap of EVOMMUNE (EVMN)?
